Toviaz FDA Approval History
FDA Approved: Yes (First approved October 31, 2008)
Brand name: Toviaz
Generic name: fesoterodine fumarate
Dosage form: Extended Release Tablets
Company: Pfizer Inc.
Treatment for: Urinary Frequency
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Development Timeline for Toviaz
|Oct 31, 2008||Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.